Published by Nicolas Tierney
June 27, 2019
Regenerative medicine, broadly defined, is one of this century’s major medical trends. Its “value” is estimated conservatively in excess of $100 billion, with substantial growth forecast for many decades. Much of this value will inevitably accrue to product manufacturers and other non-practitioners. However, it should also accrue to those clinicians delivering evidence-based and regulatorily-compliant regenerative medicine procedures (“RMP’s”).